

Regulated Information

Disclosure in accordance with the law of May 2, 2007

ThromboGenics NV increases share capital through warrant exercises

Leuven, Belgium – May 3, 2013 - ThromboGenics NV (NYSE Euronext: THR), an integrated biopharmaceutical company focused on developing innovative ophthalmic medicines, announced today a capital increase arising from employee warrant exercises.

Since its inception in 2006, ThromboGenics has used warrant plans to incentivize personnel and management and have them share in the success of the company. Following warrant exercises during the exercise period in April 2013, ThromboGenics issued 234.125 new ordinary shares for a total capital increase (including issuance premium) of €2.960.992,50.

To date, ThromboGenics total share capital amounts to €162.404.449,73; the total number of securities conferring voting rights is 36.094.349 which is also the total number of voting rights (the "denominator"). All voting rights are of the same category.

As a result of this capital increase, Biggar LTD has passed a threshold of 5% of the total outstanding warrants.

As per 3 May 2013, based on the transparency notifications received, ThromboGenics NV has been informed of the following major shareholdings:

Shareholder	Number of shares	% outstanding shares
Thomas Clay	2.192.322	6,4%
Landon Clay	1.831.461	5,1%
Biggar Ltd	1.800.000	4,9%
Oppenheimer Funds	992.337	2,7%

- End -

For further information please contact:

ThromboGenics

Chris Buyse, CFO

Tel: + 32 16 75 13 10

chris.buyse@thrombogenics.com

About ThromboGenics

ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines. The Company's lead product, JETREA® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013. In Europe, it has been approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.

In March 2012, ThromboGenics signed a strategic partnership with Alcon (Novartis) for the commercialization of JETREA® outside the United States. Under this agreement, ThromboGenics could receive up to a total of €375 million in up-front and milestone payments. It will receive significant royalties from Alcon's net sales of JETREA®. ThromboGenics and Alcon intend to share the costs equally of developing JETREA® for a number of new vitreoretinal indications.

ThromboGenics is also further exploring anti-PIGF (Placental Growth Factor), formerly referred to as TB-403, for the treatment of ophthalmic and oncology indications.

ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction. No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.